The Ministry of Health and Social Services has addressed recent social media claims regarding the overpricing of Quinine 300mg tablets, a critical treatment for malaria.

These concerns arise during a malaria outbreak, which has seen over 76,000 cases reported from December last year to the present, resulting in 132 deaths.

In response to allegations of inflated pricing for anti-malarial medication, the Ministry clarified that these claims have emerged amid a significant malaria crisis.

The Ministry also dismissed assertions that Quinine is no longer necessary, describing such claims as misleading and detrimental to public trust in the national malaria treatment program.

While Artemether-Lumefantrine is the primary treatment, Quinine 300mg tablets remain essential as a second-line option, particularly for pregnant women and patients who experience adverse reactions to first-line medications.

Given the urgency of the situation, emergency procurement procedures were 

implemented. Multiple suppliers were approached, and West Pharmaceuticals was chosen for their ability to deliver within one week, significantly faster than others.

Despite their higher price per pack, the Ministry prioritized timely delivery to avert potential medicine shortages and save lives. Purchasing directly from manufacturers proved unfeasible due to high minimum order requirements and lengthy lead times.

No payments have been made yet, as the shipment is still undergoing inspection. A thorough investigation is in progress, and the Ministry emphasized its commitment to transparency and responsible use of public funds.

The public is urged to refrain from spreading misinformation that could obstruct malaria control efforts. Additionally, the Ministry is reviewing its processes to enhance future emergency purchases.